NanoViricides CEO Dr. Seymour to Present at the LD Micro Invitational Conference Today, June 4th
04 June 2014 - 9:00PM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) reports that
its CEO, Dr. Eugene Seymour, MD, MPH, will be presenting at the LD
Micro Invitational Conference today at 5pm Pacific Time at the Luxe
Sunset Boulevard Hotel in West Los Angeles.
Dr. Seymour will provide an update on the Company’s drug
programs, and the cGMP clinical product manufacturing facility.
This facility in Shelton, CT, is nearing completion of the
construction phase and is entering the facility validation phase.
The fully customizable manufacturing facility will enable cGMP
manufacture of all of our nanoviricides® drug candidates in
kilogram scale, sufficient for pre-IND and human clinical
studies.
The Company intends to begin the safety/toxicology studies of
its Injectable FluCide™ drug candidate as soon as feasible. The
Company is in the process of producing sufficient drug substance
for these studies at its existing facility. This injectable FluCide
drug candidate is intended to treat hospitalized patients with
influenza. It is designed to be broad-spectrum, and thus is
expected to work against most, if not all, forms of influenza
virus, including epidemic, pandemic (e.g. H1N1/2009), high path
influenzas such as H3N2, H7N9, and “bird flu” such as H5N1. This
drug candidate has demonstrated an unparalleled 1,000-fold
reduction in lung viral load in a lethal animal model study. In the
same study, the current standard of care, oseltamivir, (Tamiflu®,
Roche) exhibited only a 2-fold reduction in lung viral load at the
same time point.
The Company is working on five additional commercially important
drug candidates, namely: DengueCide™, HerpeCide™, HIVCide™, Oral
FluCide™ for out-patients, and a broad-spectrum antiviral drug for
viral diseases of the external eye. All of our programs are for
therapeutics to treat viral infections. Our drugs are expected to
be useful as prophylactics as well.
DengueCide has recently received orphan drug designation by the
US FDA as well as the European EMA.
NanoViricides recently received an important international
award, the “IAIR Award 2014 for Leadership in Nanomedicines in the
North American Sector”.
The market size for our first drug, injectable FluCide, for use
in hospitalized patients with influenza, is estimated to be in
excess of a billion dollars. There is no satisfactory treatment
available for this indication at present. In addition, the overall
influenza market is expected to be in several billions of dollars.
The total market size addressed by the Company’s current drug
programs is estimated at about $40 billion or more.
The Company currently has approximately $36.6 million
cash-in-hand and cash-like-instruments. These funds are estimated
to be sufficient for taking at least one of our drug candidates
through initial human clinical trials, and possibly take another
drug candidate into human clinical trials.
Dr. Seymour’s presentation will be made available on our website
(www.nanoviricides.com).
About LD Micro:
is LD Micro is a newsletter firm that focuses on finding
undervalued companies in the micro-cap space. Since 2002, the firm
has published reports on select companies throughout the year. LD
Micro concentrates on finding, researching, and investing in
companies that are often overlooked by institutional investors. It
is a non-registered investment advisor. For more information or to
register for the event, please visit www.ldmicro.com or call (408)
457-1042.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon, 310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Apr 2024 to May 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From May 2023 to May 2024